Trial Profile
A Phase I, Open-Label, Two-Part, Multicenter Perjeta Subcutaneous Dose-Finding Study in Combination With Herceptin in Healthy Male Volunteers and Female Patients With Early Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2019
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer; Early breast cancer
- Focus Pharmacokinetics
- Sponsors Roche
- 20 Dec 2018 Results published in the Journal of Clinical Pharmacology
- 11 Jun 2018 Status changed from active, no longer recruiting to completed.
- 05 Jan 2018 Planned End Date changed from 15 Aug 2018 to 19 Jun 2018.